Placebo for Rosuvastatin

DRUG4 trials

Sponsors

AstraZeneca AB, Göteborg University, Organon and Co, Merck Sharp & Dohme LLC

Conditions

Abdominal ObesityHypercholesterolaemiaHypercholesterolemiaHyperlipidemia

Phase 3

Rosuvastatin in Visceral Adiposity

CompletedNCT01068626

Göteborg UniversityAbdominal Obesity

Start: 2006-05-31End: 2008-12-31Updated: 2015-08-24

A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)

CompletedNCT02741245

Organon and CoHypercholesterolemia

Start: 2016-06-09End: 2017-01-18Updated: 2024-05-16

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Active, not recruitingNCT07216482

Merck Sharp & Dohme LLCHyperlipidemia

Start: 2025-11-11End: 2026-11-05Updated: 2026-09-01

A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin compared with Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve Patients

Not yet recruitingCTIS2026-525642-30-00

AstraZeneca ABHypercholesterolaemia

Target: 145Updated: 2026-10-06